FBR & Co. Still Sidelined on Intercept Pharma (ICPT) Amid M&A Chatter; Sees Takeout Around $192/Share
Tweet Send to a Friend
FBR & Co. is commenting on Intercept Pharma (Nasdaq: ICPT) amid recent M&A speculation. Reports out earlier in the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
